Urologists 'Outraged' Over PSA Test Challenge
The report said that over-diagnosis and overtreatment becomes an "inevitability" with PSA testing, which "means that many men will experience the adverse effects of diagnosis and treatment of a disease that would have remained asymptomatic throughout their lives. Assessing the balance of benefits and harms requires weighing a moderate to high probability of early and persistent harm from treatment against the very low probability of preventing a death from prostate cancer in the long term," the report said.
Siegel said the report ignores or fails to explain the dramatic decrease in deaths from prostate cancer over the last several decades.
"About 250,000 men are diagnosed with prostate cancer each year. That has stayed pretty stable. It is the death rates that have come down significantly," he says.
"In the last 30 years the deaths have dropped from 48,000 to 28,000 a year. The surgery is better. The radiation is somewhat better. But there haven't been significant advances except in some of the surgical techniques to explain this, other than screening."
- CMS Mulls Income-Adjusting MA Stars
- As Retail Clinics Surge, Quality Metrics MIA
- Providers' Push to Consolidate Roils Payers
- Providers Prep for New Payment Models as Population Health Grows
- Former NQF Co-Chair Linked to Conflicts of Interest in Journal Probe
- No Employee Satisfaction, No Patient-Centered Culture
- 3 Ways to Rev Employee Development Programs
- 6 Not-So-Good Reasons for Avoiding Population Health
- Medicare Cost, Quality Data Tools Weak, Says GAO
- Aligning Executive Compensation with Provider Mission